Overview of Tadalafil-Teva
Quick Facts
| Property | Description |
|---|---|
| Active Ingredient | Tadalafil (INN) |
| Form | Oral Tablet |
| Pharmacological Class | Phosphodiesterase type 5 (PDE5) inhibitor |
| Origin | Synthetic |
| Route of Administration | Oral |
Tadalafil-Teva: Classification and Composition
Tadalafil-Teva is a synthetic, single-ingredient medicinal product whose active component is the substance Tadalafil (INN). The drug is formally classified as a Phosphodiesterase type 5 (PDE5) inhibitor, a group of agents clinically recognized for their role in modulating vascular function. This specific product, a branded generic manufactured by Teva Pharmaceutical Industries, is supplied as an oral tablet for systemic delivery.
As a compound manufactured via chemical synthesis, Tadalafil's specific chemical structure provides a key differentiating characteristic: its long-acting profile compared to other medications in its class. Tadalafil is designed to maintain therapeutic effects over an extended period. This classification and its core component are critical, as they immediately define the product's function: selectively modulating the PDE5 enzyme to achieve smooth muscle relaxation and vasodilation.
How Tadalafil-Teva Is Designed to Work
The general purpose of Tadalafil-Teva is to facilitate improved localized blood flow to target tissues by acting on the Nitric Oxide (NO) signaling pathway. The medication achieves this by selectively inhibiting the PDE5 enzyme, which is normally responsible for the breakdown of cyclic Guanosine Monophosphate (cGMP), a key chemical messenger.
By protecting and preserving cGMP, the drug effectively enhances the body's natural signals, promoting the smooth muscle relaxation required for blood vessels to widen in specific areas. This physiological response is the foundational action that allows the medicine to restore or enhance functional circulation where it is physiologically impaired, which is the underlying challenge in conditions like certain forms of vascular insufficiency.
Regulatory References

